Get started
Author

Lucinda A. Hall

Observed names: Lucinda Ann Hall, Lucinda Hall
ORCID: 0000-0003-3582-6462
Observed ORCID: 0000-0003-3582-6462
OpenAlex ID: A5003268911
Evaluation of [89Zr]Zr-DFO-2Rs15d Nanobody for Imaging of HER2-Positive Breast Cancer
2023 · Maxwell Ducharme, Lucinda Hall, et al. · Molecular Pharmaceutics · 29
PDF
Inter‐ and intraspecific variation in mycotoxin tolerance: A study of four Drosophila species
2022 · Prajakta P. Kokate, Morgan Smith, et al. · Ecology and Evolution · 10
PDF
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study
2023 · Kai Qin, Kazuhito Honjo, et al. · PLoS Medicine · 9
PDF
Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies
2022 · Garima Kumar, Sarah Sterrett, et al. · Protein Engineering Design and Selection · 8
PDF
SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia
2022 · Kai Qin, Kazuhito Honjo, et al. · medRxiv · 1
PDF
Improved Calreticulin Nanobody by Framework Engineering
2026 · Logan Mavar, Mikhail Pavlenok, et al. · Protein Engineering Design and Selection
Improved Calreticulin Nanobody by Framework Engineering
2026 · Logan Mavar, Mikhail Pavlenok, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract 2543: Serum calreticulin as a promising biomarker for cancer screening
2026 · Jasmine Watts, Lucinda Ann Hall, et al. · Cancer Research
Generation of a Synthetic Single Domain Antibody Library for Radiopharmaceutical Ligand Discovery
2025 · Lucinda Hall, Rachael Guenter, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract 574: Detection of tumor cell surface calreticulin after doxorubicin treatment using a novel radiolabeled nanobody
2025 · Rachael Guenter, Yuvasri Golivi, et al. · Cancer Research
Works count: 10
Citation count: 57
H-index: 4
I10-index: 2
Year
Topic
Type